Drug Profile
DTaP vaccine paediatric - GSK
Alternative Names: Diphtheria tetanus-acellular pertussis vaccine - GlaxoSmithKline; InfanrixLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Pertussis; Tetanus
Most Recent Events
- 10 Jul 2003 The FDA approved Infanrix® as the fifth consecutive dose in the paediatric vaccination schedule
- 02 Mar 2001 GlaxoSmithKline has applied to the US FDA for approval of Infanrix® as the fifth consecutive dose in the paediatric vaccination schedule
- 22 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline